New research suggests GLP-1 drug treatments for obesity primarily lead to the loss of fat mass while preserving muscle mass, as presented at ECO2026 in Istanbul.
New findings from a study presented at the European Congress on Obesity (ECO2026) held in Istanbul, Turkey highlight that patients treated with GLP-1 drugs for obesity experience significant weight loss primarily through the reduction of fat mass. According to the research, most of the weight lost is attributed to fat mass, ranging between 80% and 85%. Importantly, the study also indicates that relative muscle mass remains largely intact during this treatment period.
These results are particularly promising as they suggest that GLP-1 drugs may be a viable option for individuals seeking to manage obesity without compromising their overall body composition. The preservation of muscle mass is crucial in maintaining metabolic health and preventing adverse side effects often associated with rapid weight loss programs.
Further analysis will be necessary to confirm these findings and explore the long-term implications of this treatment approach on both fat and muscle metabolism.
